Replies to post #714449 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

The problem is NWBO hasn't even started on pricing model or hiring contractors for the NICE submission.

what part of this

There are 200,000 GBM patients worldwide each year. After UK approval MD's worldwide will start directing their patients to DCVAXL. With a patient's life depending on it Im sure at least 5% to 10% can afford DCVAXL treatment of let's say $150k.

is it you don't understand?

No NICE needed smartie pants